Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: 2 - What They Never Told You

Merck, Moderna Cancer Vaccine Breakthrough Could Be Catalyst the mRNA ETF Trade Has Been Waiting For

Moderna Inc.’s (NASDAQ:MRNA) latest cancer-vaccine breakthrough could be doing more than sending its stock sharply higher. It may be giving investors a reason to revisit an mRNA investment thesis that has largely been defined by COVID-19. ETFs tied to precision medicine names are also getting a boost.

Benzinga

Moderna Stock Soars More Than 100% on Cancer Vaccine Breakthrough: What Investors Are Betting On

Moderna shares surged after its personalised mRNA cancer treatment met key Phase 3 trial endpoints in melanoma with Merck's Keytruda.

International Business Times UK

Stocks Snap Losing Streak as Treasury Yields Ease: Stock Market Today

Yields on the 10-year and 30-year Treasuries pulled back Wednesday after the Treasury Department announced new buyback levels.

Kiplinger

From analysis to the latest developments in health,
read the most diverse news in one place.

Trump Adds to Wealth With Moderna Stock Gains: Here’s How Much President Made

Moderna Inc. (NASDAQ:MRNA) stock soared Wednesday after the company and Merck reported positive Phase 3 results for a personalized mRNA cancer vaccine, marking a major milestone for the emerging technology. Shares jumped more than 100%, reaching levels not seen since May 2024.

Benzinga

US stocks: US market rises as yields ease, Moderna lifts healthcare stocks

US stock markets enjoyed a boost as easing bond yields and a spike in Moderna shares contributed to a favorable trading environment. Despite the Federal Reserve's minutes highlighting inflation concerns and discussions on rate hikes, investors remained optimistic. The Treasury's announcement of liquidity support revitalized riskier assets, particularly in tech…

The Economic Times

'Breakthrough' mRNA cancer drug curbs melanoma in large trial

WASHINGTON (UNITED STATES) - US drugmakers Merck and Moderna said Wednesday a personalized cancer treatment had shown success in reducing the recurrence of melanoma tumors in a late-stage trial hailed by experts as a "breakthrough."

Bangkok Post

Breakthrough Personalized mRNA Vaccines Are Highly Effective Against Melanoma Skin Cancers

The vaccine could be available as soon as 2027.

Reason

Read news from The Economist, FT, and more,
with one subscription

Moderna's and Merck's personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring

The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.

Fortune

Huge Unusual Put Options Volume in Merck - Is MRK Stock Overvalued?

A Barchart report shows that despite recent strong Q2 results and a 10% spike in Merck stock today, an unusually large volume of put options has traded at a much lower strike price. Is MRK stock overvalued?

Barchart

This Analyst Just Upgraded Moderna as MRNA Stock Skyrockets on Cancer Vaccine Results

Moderna stock rips higher on a major cancer breakthrough. The announcement led William Blair to upgrade MRNA shares to "Outperform."

Barchart

Stocks climb as US Treasury acts to support bonds

Investors weighed broadly in-line inflation figures although core data surprised to the upside.

Evening Standard

Moderna stock more than doubles after skin cancer breakthrough announcement

IN FULL

The Independent UK

Moderna Shares Double Overnight Because a Made-to-Order mRNA Vaccine Actually Beats Skin Cancer

Moderna's personalised mRNA cancer vaccine, intismeran, significantly reduces melanoma recurrence in a Phase 3 trial, doubling the company's stock value and marking a milestone in cancer treatment.

International Business Times UK

Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test

Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times

Possible Skin Cancer Vaccine Shows Promise In Late Stage Trial. Moderna Stock Skyrockets.

The late-stage clinical trial was described as a "landmark moment."

The Economic Times

Moderna shares soar 159% in a day after cancer vaccine succeeds in late-stage trial

Moderna shares surged after its personalized mRNA cancer vaccine trial showed positive results. The treatment, combined with Keytruda, reduced melanoma recurrence and spread significantly. This marks the first successful late-stage trial for an mRNA cancer vaccine. The findings offer hope for future growth beyond COVID-19 vaccines. Discussions with regulators are…

The Economic Times

US stocks: US market regains ground as bond yields ease; healthcare stocks rally

Major stock indexes recovered on Wednesday after a prior day's decline. Moderna shares surged significantly following positive cancer therapy trial results. Government bond yields eased from highs, boosting investor risk appetite. Retailers like Target and Lowe's reported quarterly results, influencing consumer spending views. Geopolitical developments and Federal Reserve minutes remained…

The Independent UK

Skin cancer breakthrough after experimental mRNA drug found to prevent disease returning

More than 8,500 Americans are expected to die of melanoma this year

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily

Merck Puts a Decade Timeline on the MMR Split Order as Single Disease Shots Remain Unlicensed

Merck and GSK say separate measles, mumps, and rubella shots could take up to a decade to reach US pediatric offices. What families face now.

The Economic Times

Trump’s vaccine overhaul could bring more shots, higher costs for US families

President Donald Trump's vaccine plan faces significant financial and logistical hurdles. Drugmakers must develop new manufacturing processes and conduct extensive clinical studies. Separating vaccines could lead to more appointments and increased costs for families. Public health experts question the scientific basis for the proposed changes. States retain authority to mandate…

The Independent UK

Trump's vaccine plan would require millions of individual shots last used decades ago

The biggest obstacles to President Donald Trump’s order on vaccines may be the logistical challenges it poses for U.S. parents, health providers and drugmakers

The Conversation

Executive order on vaccines bypasses an evidence-based process that has kept kids safe

President Donald Trump signed an executive order on Aug. 10, 2026, calling for the combined measles, mumps and rubella vaccine to be given as three separate shots at three separate appointments. The combined MMR vaccine is currently given at 12 to 15 months of age and again between ages 4…

Medical Daily

Weekly HIV Pill Held Viral Suppression as Well as Daily Therapy in Phase 3 Trial

A once-weekly HIV pill matched daily therapy for viral suppression in a phase 3 trial. It is not approved yet. Here is what the data show.

Barchart

Merck & Co’s Stock: Analyst Estimates & Ratings

Merck has outperformed the broader market over the past year, and analysts remain optimistic about the stock.

Medical Daily

Once-Weekly HIV Pill Held Viral Suppression as Well as Daily Treatment in Two Phase 3 Trials

Two phase 3 trials found that a weekly islatravir and lenacapavir tablet matched daily HIV therapy at 48 weeks. Here is what the data show.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.